Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

This study has been withdrawn prior to enrollment.
(Mutual decision by site and sponsor because of difficulty recruiting Patients.)
Sponsor:
Information provided by (Responsible Party):
Onconova Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT00867061
First received: March 19, 2009
Last updated: November 27, 2012
Last verified: November 2012
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: September 2010
  Estimated Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)